Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
Asthma
About this trial
This is an interventional treatment trial for Asthma focused on measuring Pediatry, EPAAC, atopic Children, prevention of asthma, Levocetirizine, Xyzal
Eligibility Criteria
Inclusion Criteria: Inclusion criteria which must be verified at the end of first 18-months treatment (Visit 9) Having completed the previous 18-month treatment period of the EPAAC trial - NCT00152464 Exclusion Criteria: None
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
Placebo Comparator
LCTZ-LCTZ
LCTZ-PLC
PLC-PLC
Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)